Video

Dr. Landgren Discusses Risk and Treatment in Myeloma

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the relationship between risk and treatment in patients with multiple myeloma.

In multiple myeloma an important decision needs to be made regarding whether blood tests or other tests should be done to choose therapy in high-risk patients or if standard-risk patients should be chosen to receive the best drugs. One could argue, Landgren says, that these standard-risk patients will have the greatest upside. As high-risk patients have only a slightly improved outcome even with the best therapies, it may be time to rethink and give this population completely different agents.

In addition, the duration of therapies may need to change. The true role of extended dosing and maintenance therapy needs further investigation, Landgren says, as well as the role of measuring responses using minimal residual disease. Clinical trials examining new agents require complete response as an endpoint; however, Landgren believes minimal residual disease could be a new endpoint for these trials. As a consensus needs to be reached to define this new endpoint, the talk now is essentially focused on a cure for multiple myeloma.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine